

# **Clinical profiles and risk factors of hepatocellular carcinoma with viral hepatitis at a tertiary hospital in Mogadishu**

Mohammed A Hassan<sup>1</sup>; Ahmed M Bashir<sup>2</sup>; Isaiah G Akuku<sup>3</sup>; Janet Evelia<sup>4</sup>; Ahmed Aweis<sup>5</sup>

<sup>1</sup> Department of Internal Medicine, Dr. Sumait Hospital, Faculty of Medicine, and Health Sciences, SIMAD University, Mogadishu Somalia

<sup>2</sup> Department of Internal Medicine, Mogadishu Somali-Turkey Recep Tayyip Erdoğan Training and Research Hospital, Mogadishu, Somalia

<sup>3</sup> Department of Microbiology, Institute of Tropical and Infectious Diseases, University of Nairobi, Nairobi, Kenya

<sup>4</sup> Department of Medicine, The Aga Khan University Hospital, Nairobi, Kenya

<sup>5</sup> Department of Public Health, Benadir University, Mogadishu, Somalia

## Abstract

**Objectives:** To describe the clinical profiles of HCC patients with or without viral hepatitis. Additionally, to evaluate the risk factors for HCC with viral hepatitis.

**Methods:** In a cross-sectional study, 52 HCC patients diagnosed by imaging in Mogadishu were enrolled. Serum liver blood samples were taken, and sociodemographic and risk data recorded. In addition, we used logistic regression to evaluate relevant sociodemographic and clinical risk factors for HCC with viral hepatitis.

**Results:** Of all patients, 86.5% were men, a median age of 64.0 years (interquartile range [IQR]: 51.5 to 72.0). 50% of the patients were cases of HBV or HCV, 44.2% was HBV and 15.4% were HCV. Diabetes, fatty liver disease and underweight was present in 23.1%, 30.8%, and 32.7%, respectively. The median of Gamma-glutamyl transferase (GGT) was 176.0 U/L (IQR 106.0–302.2 U/L; normal 1-60 U/L) and alpha-fetoprotein was 1337.5 ng/ml (IQR 566–2625; normal 0-8.78 ng/ml). Aspartate aminotransferase (AST) (121.5; IQR 64.5–198.0; normal range 0-31U/L), alkaline phosphatase (ALP) (173.5; IQR 125.2–232.5; normal 30-155 U/L) and direct bilirubin 0.5 (0.2–0.9; normal 0.01-0.4mg/dl) were also elevated. AST (median greatest dimension 164.5 U/L versus 70.0 U/L;  $p<0.001$ ) and ALT (55.0 versus 30.0;  $p=0.048$ ), and the distribution of international normalized ratio (INR) was higher (69.2% versus 34.6%;  $p=0.025$ ) in viral hepatitis-positive patients than the non-viral group. Adjusted analysis showed INR was associated with viral hepatitis-HCC.

**Conclusion:** Most HCC patients were old and presented with HBV infection.

Age, AST, ALT and INR biomarkers appeared to be influencing factors of viral hepatitis with HCC. The coexistence of viral hepatitis and metabolic factors enhanced the HCC development. In the primary care setting, evaluating the clinical profile could support risk stratification for HCC patients, including viral hepatitis-positive patients, timely detection, and decision-making in patient management.

**Keywords:** Hepatocellular Carcinoma; Viral Hepatitis; Risk factors; Somalia

## Introduction

Liver cancer is one of the leading causes of cancer-related deaths globally,

accounting for 905,677 new cases and 830,180 deaths in 2020 (1).

Hepatocellular carcinoma (HCC), also referred to as primary liver cancer, is

the most common type of liver cancer and Africa's fourth most common

cancer (2). Viral hepatitis is a major public health issue that affects hundreds

of millions of people worldwide (3). There are currently five recognized viral

hepatitis types that include hepatitis A, B, C, D, E, and G viruses, with

Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) strongly associated

with HCC accounting for 80% of its development (3–8).

In Africa, HBV and HCV are the primary HCC aetiologic agents (2,9,10),

with over half of HCC cases caused by HBV, while approximately 25% are

caused by HCV (10); however, in some African countries, Egypt in particular,

HCV is the leading cause of HCC (11). Unfortunately, in Sub-Saharan Africa,

most HCC diagnosis is made late in the disease cycle when surgery cannot be

done. Therefore, primary HCC prevention is reliant on preventing and treating

viral hepatitis, especially HBV and HCV, and other underlying aetiologies

(12).

Apart from the viral agents, the other important risk factors for HCC are

metabolic factors (diabetes, obesity-related non-alcoholic steatohepatitis

[NASH], non-alcoholic fatty liver disease [NAFLD], hereditary

haemochromatosis). Additionally, carcinogenic or toxic factors (cigarette

smoking, alcohol, and aflatoxins exposures) and immune-related factors

(primary biliary cirrhosis or cholangitis, and 1-antitrypsin deficiency and

autoimmune hepatitis) (13,14). These have been well studied outside sub-Saharan African.

Unfortunately, when HCC symptoms are manifested, the disease is in an advanced stage with poor prognosis, despite that the disease has a prolonged sub-clinical duration which provides a greater opportunity to detect the disease early for potential cure. (15). Ultrasonography, computed tomography (CT) and magnetic resonance imaging (MRI) are the commonly used imaging to identify the size of liver nodules in HCC, and tumor markers such as Alpha-fetoprotein since invasive method of biopsy might cause bleeding(16). It is also shown that alpha-fetoprotein is more sensitive in detecting HCC early in pre-clinical stage than the other tumor biomarkers such as Des-gamma carboxy-prothrombin (DCP) and lectin-bound AFP (AFP-L3)(15).

HCC is more frequent in Somalia (17), with a pooled prevalence of 14% to 29% (18); however, there is a scarcity of reliable or up to date data on the clinical and risk profile data for HBV- or HCV-related HCC in the country. Moreover, the HCC surveillance rates are also disappointingly nonexistent or low in Somalia, affecting clinical screening uptake (19). Therefore, exploring the clinical profiles and risk factors in Somalia may be useful in providing a theoretical and a practical foundation for early detection, curative options, preventing, and controlling HCC in the country. In addition, identifying markers for early diagnosis and risk stratification might benefit HCC patients in Somalia and inform a patient-centered research agenda. Therefore, in a cross-sectional study of HCC patients in Mogadishu, Somalia, we described the clinical profiles of HCC patients with or without viral hepatitis. Additionally, we explored the risk factors for HCC with viral hepatitis.

## Methods

### *Study Setting and population*

This was a cross-sectional study of 52 conveniently sampled patients diagnosed with HCC through imaging and laboratory test between August 2020 to August 2021 at Mogadishu Somali-Turkey Recep Tayyip Erdoğan Training and Research Hospital, Mogadishu, Somalia. This hospital, which opened its doors in Mogadishu, Banadir region, in 2015, is the country's best-equipped referral hospital in terms of medical technology. The hospital offers tertiary care and is equipped for surgical operations and imaging procedures, such as computed tomography, ultrasound, magnetic resonance imaging, and image-guided biopsies. We excluded patients who did not provide informed consent to participate and those suffering from other severely debilitating illnesses, ostensibly frail for unknown reasons and thus unable to communicate and patients who did not provide informed consent to participate.

### *Study procedures and blood sampling*

All enrolled participants were interviewed using a structured questionnaire and sociodemographic data such as (age in years, sex, marital status, education, occupation, and average monthly income [United States Dollars]). We also gathered anthropometric measures (weight in kilograms and height in meters). In addition, we collected clinical history data (time since HCC was first diagnosed, HCC diagnosis method, history of HCC hospitalization, smoking status, smoking duration, family history of HCC, history of diabetes, history of fatty liver, history of physician-diagnosed liver disease, and markers of serum liver activity (Aspartate aminotransferase [AST], alanine aminotransferase

[ALT], Alkaline phosphatase[ALP], Gamma-glutamyl transferase [GGT], International normalized ratio [INR] and Alpha-fetoprotein [AFP]) were collected. The tests were performed on a Mindray analyzer (Mindray) and captured.

### ***Blood sampling***

We obtained blood samples from participants through standard venipuncture methods. In addition, we performed biochemistry tests, which included assessing serum activity levels/profiles, HBV, and HCV.

### ***Study definitions***

Viral hepatitis was defined as a mono-infection with either HBV or HCV or an HBV/HCV co-infection. The dual infection may occur and even persist in the same patient since they have similar transmission routes (20). Body mass index (BMI) was calculated from measured height and weight and classified as normal weight (18.5–24.9 kg/m<sup>2</sup>), overweight (25–29.9 kg/m<sup>2</sup>), and obese ( $\geq 30$  kg/m<sup>2</sup>). Current or past smoking history was self-reported by participants. Diabetes mellitus was defined as self-reported type 1 or 2 diabetes mellitus. Serum liver chemistries including AST (normal range, 0–31U/L), ALT (normal range, 0–45U/L), ALP (normal range, 30–155 U/L), GGT (normal range, 1–60 U/L), Total bilirubin (normal range, 0.30–1.10mg/dl), direct bilirubin (normal range, 0.01–0.4mg/dl), INR (normal range, 0.8–1.2.) and AFP (normal range, 0–8.78ng/ml) values were reported, and abnormal/elevated values were defined as any parameter with a value greater than the upper limit of the normal range. The AST, ALT, ALP, GGT, TBIL, DBIL, INR, and AFP threshold values were chosen based on the normal ranges used at MSTH.

### ***Ethics statement***

The Mogadishu Somali-Turkey Recep Tayyip Erdoğan Training and Research Hospital (MSTH) ethics committee reviewed and approved the study in accordance with the Helsinki Declaration. All participants provided written informed consent before participation (28.072020, Reference number – MSTH/4125) and data were analyzed anonymously.

### ***Statistical Analysis***

Sociodemographic, clinical variables and markers of serum liver activity levels were described overall and by HBV or HCV status since virtually all patients had elevated alpha-fetoprotein (AFP) and gamma-glutamyl transferase (GGT) above indicated cut-off level. The Shapiro Wilk test was used to test the normality of the continuous data. The continuous variables were then presented as median and their respective interquartile range (IQR: Q1 to Q3), while the categorical variables were described as frequencies and percentages. Statistical differences between groups were assessed using Fisher's exact test for categorical variables and Mann-Whitney U two-sample test or Kruskal-Wallis test for continuous data, appropriately.

In further analysis, we evaluated the risk factors of HCC with viral hepatitis using a logistic regression model considering the sociodemographic, clinical, and aflatoxin-related factors. We used  $p$ -value=0.2 as a threshold for both covariate entry and exiting the final model and added clinically important covariates based on past literature. Results were expressed as adjusted odds ratio (AOR) and their 95% confidence intervals (CI). All the analyses were carried out in R (Version 4.1.2) and reported at a 5% level of statistical significance.



## Results

### Profiles of study participants

Our study included 52 patients whom 75% (n=39) was diagnosed with dual imaging of Ultrasound and CT Scan, while 13.5% (n=7) and 11.5% (n=6) diagnosed with Ultrasound and CT scan, respectively. The participants median age was 64.0 (interquartile range [IQR]: 51.5 to 72.0). Males were 45 (86.5%) while females were seven. Neither of the patients in our study was HIV-positive nor consumed alcohol. Infection with viral hepatitis was in 26 patients (50.0%), while separately HBV and HCV were in 44.2% (n=23) and 15.4% (n=8), respectively, by serology or physician diagnosis. HBV/HCV uninfected patients were older than HBV/HCV infected patients (median greatest dimension, 70.0 versus 55.0;  $p=0.046$ ). Table 1 summarises the sociodemographic characteristics of all patients and stratified by HBV or HCV infection.

Table 1. Sociodemographic profiles of hepatocellular carcinoma patients stratified by hepatitis B virus and/or Hepatitis C virus infection

| Characteristics <sup>a</sup> | Levels                     | All HCC patients    | HCC with HBV and/or HCV | HCC without HBV and/or HCV | <i>p</i> -value <sup>b</sup> |
|------------------------------|----------------------------|---------------------|-------------------------|----------------------------|------------------------------|
| Total N (%)                  |                            | 52                  | 26 (50.0)               | 26 (50.0)                  |                              |
| Age (years)                  | Median (IQR <sup>c</sup> ) | 64.0 (51.5 to 72.0) | 55.0 (49.8 to 69.5)     | 70.0 (57.5 to 77.5)        | <b>0.046</b>                 |
| Gender, %                    | Male                       | 45 (86.5)           | 21 (80.8)               | 24 (92.3)                  | 0.419                        |
|                              | Female                     | 7 (13.5)            | 5 (19.2)                | 2 (7.7)                    |                              |
| Marital status, %            | Single                     | 4 (7.7)             | 2 (7.7)                 | 2 (7.7)                    | 0.609                        |
|                              | Married                    | 29 (55.8)           | 13 (50.0)               | 16 (61.5)                  |                              |
|                              | Divorced                   | 5 (9.6)             | 4 (15.4)                | 1 (3.8)                    |                              |
|                              | Widowed                    | 14 (26.9)           | 7 (26.9)                | 7 (26.9)                   |                              |
| Education, %                 | Illiterate                 | 4 (7.7)             | 3 (11.5)                | 1 (3.8)                    | 0.671                        |

|                                 |              |                     |                     |                     |       |
|---------------------------------|--------------|---------------------|---------------------|---------------------|-------|
|                                 | Quran        | 29 (55.8)           | 12 (46.2)           | 17 (65.4)           |       |
|                                 | Elementary   | 11 (21.2)           | 6 (23.1)            | 5 (19.2)            |       |
|                                 | Secondary    | 2 (3.8)             | 1 (3.8)             | 1 (3.8)             |       |
|                                 | Degree       | 6 (11.5)            | 4 (15.4)            | 2 (7.7)             |       |
| Occupation, %                   | Working      | 17 (32.7)           | 10 (38.5)           | 7 (26.9)            | 0.555 |
|                                 | Nonworking   | 35 (67.3)           | 16 (61.5)           | 19 (73.1)           |       |
| Average Monthly Income (USD), % | <100\$       | 25 (48.1)           | 12 (46.2)           | 13 (50.0)           | 1.000 |
|                                 | 100-500\$    | 22 (42.3)           | 11 (42.3)           | 11 (42.3)           |       |
|                                 | >500\$       | 5 (9.6)             | 3 (11.5)            | 2 (7.7)             |       |
| Weight (Kg)                     | Median (IQR) | 55.5 (50.0 to 60.0) | 54.5 (50.0 to 60.0) | 56.0 (52.0 to 60.0) | 0.912 |
| Height (M)                      | Median (IQR) | 1.7 (1.6 to 1.7)    | 1.7 (1.6 to 1.7)    | 1.7 (1.6 to 1.7)    | 0.664 |
| BMI (Kg/M <sup>2</sup> )        | Median (IQR) | 16.9 (15.0 to 18.0) | 16.9 (14.7 to 18.0) | 16.4 (15.1 to 17.9) | 0.680 |
| BMI <sup>d</sup> , %            | <18.5        | 17 (32.7)           | 11 (42.3)           | 6 (23.1)            | 0.247 |
|                                 | 18.5–24.9    | 30 (57.7)           | 12 (46.2)           | 18 (69.2)           |       |
|                                 | 25–29        | 5 (9.6)             | 3 (11.5)            | 2 (7.7)             |       |

<sup>a</sup> N represents the total sample size for the group. USD (\$), United States Dollars; Kg, Kilograms; M, Metres; BMI, Body Mass Index. HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus.

<sup>b</sup> p-value from Chi-square test or Fisher's exact test for categorical variables and unpaired two-sample Wilcoxon test for continuous variables, two-sided; bold p-values indicate statistical significance (p<0.05).

<sup>c</sup> IQR, Interquartile range.

<sup>d</sup> Body Mass Index (BMI) <18.5 (Underweight), BMI 18.5–24.9 (Normal), BMI 25–29 (Overweight).

## Clinical and laboratory characteristics of HCC patients with and without HBV or HCV

Table 2 lists the clinical and laboratory findings of the patients. Since HCC was diagnosed mainly, the time was less than one year (96.2%) and was similar in both categories of HCC patients. Most of the patients reported they had no or did not know of a family history of HCC (90.4%), while 98.1% were never smokers. Twelve

(23.1%) patients had a history of diabetes, and 16 (30.8%) had a history of Fatty Liver or physician-diagnosed liver disease.

Nearly all the serum levels were elevated for the markers. The overall median of GGT and AFP was 176.0 (106.0 to 302.2) and 1337.5 (566 to 2625), respectively but were statistically indifferent when stratified by HBV/HCV status. The median AST (greatest dimension 164.5 U/L versus 70.0 U/L;  $p<0.001$ ) and ALT (55.0 versus 30.0;  $p=0.048$ ) were higher in patients with HBV/HCV than those without HBV/HCV. INR distribution was higher (69.2% versus 34.6%;  $p=0.025$ ) in viral hepatitis-positive HCC patients than the viral hepatitis-negative HCC patients. Table 2 details the serum levels and status of HBV/HCV infection.

Table 2. Clinical and laboratory characteristics of HCC patients with and without HBV and/or HCV

| Variable <sup>a</sup>                       | Level         | All HCC patients<br>[No. of patients<br>(%) or Median<br>(Q1 to Q3)] | HCC with HBV<br>and/or HCV<br>[No. of patients<br>(%) or Median (Q1<br>to Q3)] | HCC without HBV<br>and/or HCV<br>[No. of patients (%) or<br>Median (Q1 to Q3)] | <i>p</i> -value <sup>b</sup> |
|---|---------------|--|--|--|------------------------------|
| Total N (%)                                 |               | 52   | 26 (50.0)  | 26 (50.0)  |                              |
| Time since<br>HCC first<br>diagnosed, %     | <1 year       | 50 (96.2)  | 25 (96.2)  | 25 (96.2)  | 1.000                        |
|   | 1-5 year      | 1 (1.9)  | 1 (3.8)  | 0 (0.0)  |                              |
|   | >5 year       | 1 (1.9)  | 0 (0.0)  | 1 (3.8)  |                              |
| History of<br>HCC<br>hospitalization<br>, % | Yes           | 1 (1.9)  | 1 (3.8)  | 0 (0.0)  | 1.000                        |
|   | No            | 51 (98.1)  | 25 (96.2)  | 26 (100.0)   |                              |
| Smoking<br>status, %                        | Yes           | 1 (1.9)  | 0 (0.0)  | 1 (3.8)  | 1.000                        |
|   | No            | 51 (98.1)  | 26 (100.0)   | 25 (96.2)  |                              |
| Smoking<br>duration, %                      | 5-10 years    | 1 (1.9)  | 1 (3.8)  | 0 (0.0)  | 0.333                        |
|   | >10 years     | 2 (3.8)  | 0 (0.0)  | 2 (7.7)  |                              |
| Family history<br>of HCC, %                 | Yes           | 5 (9.6)  | 1 (3.8)  | 4 (15.4)   | 0.262                        |
|   | No            | 25 (48.1)  | 15 (57.7)  | 10 (38.5)  |                              |
|   | Don't<br>know | 22 (42.3)  | 10 (38.5)  | 12 (46.2)  |                              |

|                                  |                         |                        |                        |                       |        |
|----------------------------------|-------------------------|------------------------|------------------------|-----------------------|--------|
| History of Diabetes, %           | Yes                     | 12 (23.1)              | 5 (19.2)               | 7 (26.9)              | 0.743  |
|                                  | No                      | 40 (76.9)              | 21 (80.8)              | 19 (73.1)             |        |
| Fatty Liver Disease <sup>c</sup> | Yes                     | 16 (30.8)              | 11 (42.3)              | 5 (19.2)              | 0.132  |
|                                  | No                      | 36 (69.2)              | 15 (57.7)              | 21 (80.8)             |        |
| AST                              | Median (IQR)            | 121.5 (64.5 to 198.0)  | 164.5 (123.8 to 288.2) | 70.0 (45.2 to 116.0)  | <0.001 |
|                                  | Normal (0-31 U/L)       | 6 (11.5)               | 1 (3.8)                | 5 (19.2)              |        |
|                                  | Abnormal                | 46 (88.5)              | 25 (96.2)              | 21 (80.8)             |        |
| ALT                              | Median (IQR)            | 39.0 (23.0 to 65.8)    | 55.0 (35.0 to 80.8)    | 30.0 (20.0 to 58.8)   | 0.048  |
|                                  | Normal (0-45 U/L)       | 28 (53.8)              | 10 (38.5)              | 18 (69.2)             |        |
|                                  | Abnormal                | 24 (46.2)              | 16 (61.5)              | 8 (30.8)              |        |
| ALP                              | Median (IQR)            | 173.5 (125.2 to 232.5) | 191.0 (147.0 to 218.0) | 157.0 (98.2 to 284.2) | 0.481  |
|                                  | Normal (30-155 U/L)     | 21 (40.4)              | 8 (30.8)               | 13 (50.0)             |        |
|                                  | Abnormal                | 31 (59.6)              | 18 (69.2)              | 13 (50.0)             |        |
| GGT <sup>2</sup>                 | Median (IQR)            | 176.0 (106.0 to 302.2) | 206.0 (132.0 to 327.2) | 132.5 (82.0 to 200.8) | 0.151  |
|                                  | Normal (1-60 U/L)       | 5 (9.6)                | 2 (7.7)                | 3 (11.5)              |        |
|                                  | Abnormal                | 47 (90.4)              | 24 (92.3)              | 23 (88.5)             |        |
| Total bilirubin                  | Median (IQR)            | 0.7 (0.5 to 1.4)       | 1.1 (0.5 to 1.6)       | 0.6 (0.4 to 1.1)      | 0.050  |
|                                  | Normal (0.30-1.10mg/dl) | 34 (65.4)              | 14 (53.8)              | 20 (76.9)             |        |
|                                  | Abnormal                | 18 (34.6)              | 12 (46.2)              | 6 (23.1)              |        |
| Direct bilirubin                 | Median (IQR)            | 0.5 (0.2 to 0.9)       | 0.5 (0.4 to 0.9)       | 0.3 (0.2 to 0.8)      | 0.156  |
|                                  | Normal (0.01-0.4mg/dl)  | 24 (46.2)              | 9 (34.6)               | 15 (57.7)             |        |
|                                  | Abnormal                | 28 (53.8)              | 17 (65.4)              | 11 (42.3)             |        |
| INR                              | Median (IQR)            | 1.2 (1.0 to 1.6)       | 1.4 (1.2 to 2.0)       | 1.1 (1.0 to 1.3)      | 0.001  |

|     |                      |                      |                       |                     |              |
|-----|----------------------|----------------------|-----------------------|---------------------|--------------|
|     | Normal (0.8-1.2)     | 25 (48.1)            | 8 (30.8)              | 17 (65.4)           | <b>0.025</b> |
|     | Abnormal             | 27 (51.9)            | 18 (69.2)             | 9 (34.6)            |              |
| AFP | Median (IQR)         | 1337.5 (566 to 2625) | 884.0 (460.2 to 3600) | 1614 (1052 to 2261) | 0.558        |
|     | Normal (0-8.78ng/ml) | 2 (3.8)              | 1 (3.8)               | 1 (3.8)             | 1.000        |
|     | Abnormal             | 50 (96.2)            | 25 (96.2)             | 25 (96.2)           |              |

<sup>a</sup> Body Mass Index (BMI) <18.5 (Underweight), BMI 18.5–24.9 (Normal), BMI 25–29 (Overweight); HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; ALP, Alkaline phosphatase; GGT, Gamma-glutamyl transferase; INR, International normalised ratio; AFP, Alpha-fetoprotein.

<sup>b</sup> p-value from Chi-square test or Fisher's exact test for categorical variables and unpaired two-sample Wilcoxon/Mann-Whitney U test for continuous variables, two-sided; bold p-values indicate statistical significance (p<0.05).

<sup>c</sup> Fatty Liver Disease – ever been diagnosed with fatty liver or ever been told by a doctor you have liver disease.

### Pairwise correlations for liver-related seromarkers, age and BMI

We carried out correlation analysis with continuous variables, as shown in Table 3.

We observed a significant but negative correlation between age, AST and INR.

Seromarker AST significantly and positively correlated with ALT, ALP, GGT, TBIL, DBIL and INR. ALT also significantly and positively correlated with ALP and GGT.

We also demonstrated a positive and significant correlation for ALP with GGT, TBIL, DBIL and INR. A significant positive correlation was also found between GGT and TBIL, DBIL and INR. TBIL correlated significantly with DBIL and INR.

Table 3. Spearman pairwise correlations for liver biomarkers, age and BMI (n=52)

| Variables <sup>a</sup> | Age    | BMI   | AST   | ALT   | ALP   | GGT | TBIL | DBIL | INR | AFP |
|------------------------|--------|-------|-------|-------|-------|-----|------|------|-----|-----|
| Age                    | 1      |       |       |       |       |     |      |      |     |     |
| BMI                    | 0.06   | 1     |       |       |       |     |      |      |     |     |
| AST                    | -0.30* | 0.08  | 1     |       |       |     |      |      |     |     |
| ALT                    | 0.05   | 0.12  | 0.61* | 1     |       |     |      |      |     |     |
| ALP                    | 0.14   | -0.16 | 0.32* | 0.52* | 1     |     |      |      |     |     |
| GGT                    | -0.08  | -0.10 | 0.44* | 0.33* | 0.63* | 1   |      |      |     |     |

|      |        |       |       |       |       |       |       |      |      |   |
|------|--------|-------|-------|-------|-------|-------|-------|------|------|---|
| TBIL | 0.00   | -0.14 | 0.37* | 0.24  | 0.30* | 0.35* | 1     |      |      |   |
| DBIL | 0.07   | -0.14 | 0.36* | 0.24  | 0.35* | 0.33* | 0.75* | 1    |      |   |
| INR  | -0.31* | -0.21 | 0.31* | 0.13  | 0.29* | 0.49* | 0.31* | 0.21 | 1    |   |
| AFP  | 0.02   | -0.22 | -0.21 | -0.13 | 0.11  | -0.05 | 0.00  | 0.20 | 0.14 | 1 |
|      |        |       |       |       |       |       |       |      |      |   |

<sup>a</sup> Spearman correlations ( $\rho$ ) were done for age, AST (aspartate aminotransferase), ALT (alanine aminotransferase), ALP (alkaline phosphatase), GGT (gamma glutamyl transferase), INR (international normalized ratio), AFP (alpha-fetoprotein), BMI (body mass index), and TBIL (total bilirubin), DBIL (direct bilirubin).

\* Indicates statistically significant correlation/relationship.

### Multivariable analysis of risk factors for hepatocellular carcinoma in patients with hepatitis B or C virus

A logistic regression model assessed the risk factors for HCC with HBV or HCV. The model's calibrative-ability (Hosmer-Lemeshow Test Chi-sq (8) 8.37,  $p=0.398$ ), and discriminative-ability (C-statistic = 0.822) was good. Findings show that a unit increase in INR in the univariable model (odds ratio [OR] 14.64, 95% confidence interval [CI] 3.07-120.9,  $p=0.004$ ) and in the multivariable model (adjusted OR 10.61, 95% CI 1.80-120.13,  $p=0.024$ ) was associated with HCC in patients with hepatitis B or C virus. Age, family history of HCC, BMI, and fatty liver disease were all statistically attenuated ( $p>0.05$ ). The results are summarised in Table 4.

Table 4. Risk factors for hepatocellular carcinoma in patients with hepatitis B or C virus

| Variable <sup>a</sup>    | Level                     | HCC with HBV and/or HCV | HCC without HBV and/or HCV | Logistic regression <sup>c</sup> |                              |
|--------------------------|---------------------------|-------------------------|----------------------------|----------------------------------|------------------------------|
|                          |                           |                         |                            | Univariable                      | Multivariable                |
|                          |                           |                         |                            | OR (95% CI, $p$ -value)          | AOR (95% CI, $p$ -value)     |
| Age (years)              | Median (IQR) <sup>b</sup> | 55.0 (49.8 to 69.5)     | 70.0 (57.5 to 77.5)        | 0.97 (0.93-1.00, $p=0.089$ )     | 0.98 (0.94-1.03, $p=0.407$ ) |
| BMI (kg/m <sup>2</sup> ) | BMI 18.5–24.9             | 12 (40.0)               | 18 (60.0)                  | Reference                        | Reference                    |
|                          | BMI <18.5                 | 11 (64.7)               | 6 (35.3)                   | 2.75 (0.82-9.95, $p=0.108$ )     | 1.61 (0.31-8.15, $p=0.558$ ) |

|                                  |              |                  |                  |  |   |
|----------------------------------|--------------|------------------|------------------|--|---|
|                                  | BMI 25–29    | 3 (60.0)         | 2 (40.0)         | 2.25<br>(0.33-19.10,<br>p=0.411)           | 2.75<br>(0.23-42.43,<br>p=0.426)            |
| HCC Family history               | Absent       | 25 (53.2)        | 22 (46.8)        | Reference                                  | Reference                                   |
|                                  | Present      | 1 (20.0)         | 4 (80.0)         | 0.22<br>(0.01-1.63,<br>p=0.190)            | 0.16<br>(0.01-1.46,<br>p=0.152)             |
| Fatty Liver Disease <sup>b</sup> | No           | 15 (41.7)        | 21 (58.3)        | Reference                                  | Reference                                   |
|                                  | Yes          | 11 (68.8)        | 5 (31.2)         | 3.08<br>(0.92-11.55,<br>p=0.077)           | 1.83<br>(0.39-9.00,<br>p=0.443)             |
| INR                              | Median (IQR) | 1.4 (1.2 to 2.0) | 1.1 (1.0 to 1.3) | 14.64<br>(3.07-120.9,<br>p= <b>0.004</b> ) | 10.61<br>(1.80-120.13,<br>p= <b>0.024</b> ) |

<sup>a</sup> BMI, Body Mass Index <18.5 kg/m<sup>2</sup> (underweight), BMI 18.5–24.9 kg/m<sup>2</sup> (Normal), BMI 25–29 kg/m<sup>2</sup> (Overweight); HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; IQR, interquartile range (Q1 to Q3).

<sup>b</sup> Fatty Liver Disease – ever been diagnosed with fatty liver or ever been told by a doctor you have liver disease.

<sup>c</sup> The model fitted using logistic regression for hepatocellular carcinoma with Hepatitis B or C. Number of observations = 52, Number observations in model = 52, Missing = 0, AIC = 67.5, C-statistic = 0.822, Hosmer-Lemeshow Test= Chi-sq (8) 8.37 (p=0.398). Variables/factors associated with p-values <0.2 in univariable analysis were entered into a multivariable logistic regression analysis. OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval. Bold p-values indicate statistical significance (p<0.05).

## Discussion

We described the clinical profiles of HCC patients with or without viral hepatitis and evaluated the risk factors for HCC with viral hepatitis. We described viral hepatitis as mono- or co-infection with HBV and HCV. We observed clinically significant elevated AST, ALP, GGT, direct bilirubin and AFP serum liver chemistries. We also found that nearly all patients were non-smokers, less than 10% had a family history of HCC, a fifth were diabetic, and less than a third had a history of fatty liver diseases. Furthermore, we

established that INR was positively associated with viral hepatitis-positive HCC.

Of the two hepatic viral infections in our study, HBV was the predominantly common type (44.2%), and the mono- and co-infections explained HCC in 50% of the study population. However, a considerable proportion (30.8%) of the patients had a history of fatty liver/ a physician-diagnosed liver disease was a prime aetiology of HCC in this patient group, especially in terms of non-alcoholic fatty liver and NASH (inflammation, liver damage, and fat accumulation in the liver), which are all forms of NAFLD. Moreover, like in our study, the coexistence of NAFLD and viral hepatitis, particularly HBV, has been observed frequently(21), sometimes with an inverse association(22,23). We observed that 42.3% of viral hepatitis-positive HCC patients reported fatty liver disease. Such concurrent fatty liver has been said to increase the risk of virus-associated HCC (24–26) and potentially lead to cancer in our study population. Additionally, none of the patients in our study was HIV-positive, eliminating possible synergistic interaction between HBV or HCV and HIV.

Diabetes and HCC, like other cancers, are both multifarious, distinct, and long-term, fatal diseases that have a significant impact on health(27). Our study found that diabetes was moderately prevalent and had no statistically significant association with viral hepatitis-positive HCC. This finding affirms previous studies that reported that diabetes, as a risk factor for HCC, exists independently of the availability of HBV or HCV, non-specific cirrhosis, or alcoholic liver disease (28–31).



Our study observed that the HCC patients were considerably old (median 64.0 years; IQR, 51.5 to 72.0; range, 25 to 90) but appeared comparable to the mean of 52.6 years reported in a recent retrospective Somalian study (32). Ageing is a known risk factor for HCC development (33,34), as it impairs liver function and decreases the liver's capacity to regenerate (35). We also observed that viral hepatitis–negative HCC patients were much older than the viral hepatitis group and were mostly diabetic. The previous description may be explained by NAFLD, which studies have previously reported to be associated with ageing, diabetes and concurrent viral hepatitis infection (24–26,36).

In our study, most of the patients had normal BMI (18.5–24.9 Kg/M<sup>2</sup>), and none were obese. Although obesity and diabetes are risk factors for HCC and may vary according to HBV or HCV infection status (37), as with diabetes, we did not observe a difference in BMI distribution by HBV or HCV infection status in our study. However, a considerable number of patients were underweight (32.7%).

We found that AST, ALP, GGT, direct bilirubin, INR, and AFP serum levels were markedly elevated in most of the patients in our study population. A third (34.6%) and less than half (46.2%) had elevated total bilirubin and ALT. Additionally, slightly more than half had elevated direct bilirubin (53.8%) and INR (51.9%). Elevated liver enzymes in older people are a common finding and are often linked to metabolic syndrome(33,35,38). The serum levels for GGT, AST, ALT, and ALP, appear similar to previous Saudi Arabian findings(39). It is worth mentioning that 96.2% of the patients in this study had elevated AFP levels which is a sign of poor prognosis. A study by Asaoka

et al. had shown how the elevated tumor markers including AFP are important predictors of vascular invasion that can suggest metastasis of the primary tumor and is a poor prognosis.(40)

Evidence demonstrates that cigarette smoking is associated with increased progression and severity of liver disease, particularly fibrosis and liver cancer (41–43). However, in our study, none of the patients reported consuming alcohol. Furthermore, only one reported smoking cigarette, thus eliminating the potential contribution of alcoholic liver disease to or significant effect of cigarette smoking on HCC development. Additionally, we observed that the patient who reported smoking cigarettes had elevated GGT, ALP and INR but were viral hepatitis–negative. For this patient, cigarette smoking may have had a carcinogenic or an inflammatory effect on the liver (44). This is corroborated by Wannamethee and Shaper(45), who reported a significant association between cigarette smoking with increased GGT and ALP levels but not with high AST levels.

The most frequently encountered serum liver enzyme levels in clinical practice are hepatocellular predominance with increased ALT and AST and cholestatic predominance with elevated ALP and GGT (46). AST and ALT are released into the bloodstream by damaged hepatocytes, and their activities have long been recognised as sensitive indicators of liver disease (47–49). Still, they may also reflect non-specific hepatocellular damage(50). Elevated ALT levels have also been associated with severe liver damage and serve as a diagnostic biomarker for NAFLD (51). Overall, we found a positive correlation between AST and ALT. We also observed a significant difference in the distribution of AST and ALT by viral infection status, and this could be due to acute/chronic

viral hepatitis or NASH, implying that AST and ALT may be used as prognostic or predictive biomarkers of viral hepatitis–positive HCC in this study population.

In our study, we observed abnormally higher values of GGT and ALP in viral hepatitis–positive HCC patients than in the viral hepatitis–negative HCC group; however, the difference was not statistically significant. This could be due to cholestasis or biliary obstruction, which would result in elevated GGT and ALP due to impaired bile formation, secretion, or flow. The observed elevated GGT enzyme serum levels in over 90% of the patients appeared to predict the development of HCC in our overall study population.

Serum AFP levels were elevated in over 95% of the patients and stratified by virus-infection status. Our finding is inconsistent with Giannini et al.(52)’s Italian study that had elevated AFP levels in 62.4% of HCC patients. AFP is a biomarker whose serum concentration rises in most patients with HCC; consequently, it has been utilised in the monitoring and diagnosis of or early detection of neoplasms in HCC (53,54), despite its contested role (55). It may not be an indispensable diagnostic or screening tool (56); however, our study showed that serum AFP levels were markedly elevated. Similarly, GGT has also been proposed as a potential marker for the early detection of HCC. Furthermore, the levels of the two biomarkers can also be used to determine the survival outcome; that is, the higher the levels of GGT and AFP, the poorer the survival outcome (57). However, we observed no clear linear relationship between AFP and GGT, implying that these two biomarkers are likely associated with distinct HCC characteristics (58) in our study population.

HCC is frequently diagnosed in patients with pre-existing liver cirrhosis, but it can also develop without such a condition. Liver cirrhosis and high serum ALT are two factors that may influence serum AFP elevation (56). Although we did not test liver cirrhosis in our study, we did not find a clear correlation between AFP and ALT. The interaction between ALT levels and HCC onset and development has influences serum AFP levels (56). However, nearly all the HCC patients with elevated AFP presented elevated GGT levels simultaneously.

We observed higher levels of coagulation marker (INR) in viral hepatitis-positive patients than in the viral hepatitis-negative group. The World Health Organization developed the INR standardised reporting of prothrombin time coagulation function markers (59). The INR has been used to standardise the PT value in liver diseases. The liver is essential in the synthesis of blood coagulation factors and, thus, the importance of checking levels of INR. A high level of INR indicates slower clotting of blood, hence a higher risk of prolonged bleeding.

This is among the first few studies in Somalia that provides profile and risk data for viral hepatitis-related HCC. The strength of our study is that the viral hepatitis-positive and viral hepatitis-negative groups had a balanced number of patients and detailed data on routinely tested liver enzymes and seromarkers. However, this study had several limitations. Firstly, our study had a single-centre cross-sectional design hence prognosis was largely unfeasible as the biomarkers were not measured dynamically. Secondly, some liver-or HCC-related data or co-factors that could influence the findings were not collected, such as the aflatoxins test and our inability to identify the medications used by

the patients. Thirdly, some findings were merely patient-reported and not verifiable by medical records, indicating possible recall bias. Lastly, the sample size was relatively small compared to the burden of viral hepatitis in Somalia (16), which makes it not a good representation; hence generalizability to other settings remains to be evaluated – a major limitation of our study.

In conclusion, most HCC patients present with HBV infection and are considerably old. AST, ALP, GGT, direct bilirubin, INR, and AFP serum levels were markedly elevated in most HCC patients. Age, AST, ALT and INR biomarkers appeared to be influencing factors of viral hepatitis with HCC. The HCC development appeared to have been enhanced by the coexistence of viral hepatitis and metabolic factors. In the primary care setting, evaluating the clinical profile could support risk stratification for HCC patients, including viral hepatitis-positive patients, timely detection and decision-making in patient management.

### **Acknowledgement**

We express our sincere appreciation to Musab Ahmed Nor, a Physician at Somali-Turkey Recep Tayyip Erdoğan Training and Research Hospital who has assisted us in the data collection.

### **Conflict of Interest**

There is no professional and financial conflict of interest among our authors.

### **References**

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* [Internet]. 2021;71(3):209–49. Available from: <https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660>
2. Dakurah OB, Tamandjou CRT, Zunza M, Preiser W, Maponga TG. Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review. *BMC Cancer* [Internet]. 2021;21(1):1–13. Available from: <https://www.mdpi.com/2076-0817/10/11/1366/pdf>
3. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. *Glob Hepat Program Dep HIV/AIDS* [Internet]. 2016;(June):56. Available from: <https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf>
4. Datfar T, Doulberis M, Papaefthymiou A, Hines IN, Manzini G. Viral hepatitis and hepatocellular carcinoma: State of the art. *Pathogens*. 2021;10(11):1–19.
5. Mak D, Villiers CB de, Chasela C, Urban MI, Kramvis A. Analysis of risk factors associated with hepatocellular carcinoma in black South Africans: 2000–2012. *PLoS One* [Internet]. 2018 May 1 [cited 2021 Sep 4];13(5). Available from: [/pmc/articles/PMC5931658/](https://pubmed.ncbi.nlm.nih.gov/30000000/)
6. IARC. IAC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS Hepatitis. WHO [Internet].

1993;59(1):37–72. Available from:

[https://publications.iarc.fr/\\_publications/media/download/1986/ea9636d9c3b1d2db49e55de765cef8a28cd3791b.pdf](https://publications.iarc.fr/_publications/media/download/1986/ea9636d9c3b1d2db49e55de765cef8a28cd3791b.pdf)

7. McGlynn KA, Evans AA, Thomas London W. Epidemiology of Viral Hepatitis B-related Hepatocellular Carcinoma. Chronic Hepat B C Basic Sci to Clin Appl [Internet]. 2012;142(6):71–97. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338949/>
8. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR, et al. HHS Public Access prevention and management. 2019;16(10):589–604. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813818/>
9. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Heal [Internet]. 2020;8(2):e180–90. Available from: [http://dx.doi.org/10.1016/S2214-109X\(19\)30488-7](http://dx.doi.org/10.1016/S2214-109X(19)30488-7)
10. Mbaga DS, Kenmoe S, Kengne-Ndé C, Ebogo-Belobo JT, Mahamat G, Foe-Essomba JR, et al. Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa: A meta-analysis including sensitivity analyses for studies comparable for confounders. PLoS One [Internet]. 2022;17(1 January):1–23. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0262903>
11. Yang JD, Mohamed EA, Aziz AOA, Shousha HI, Hashem MB, Nabeel MM, et al. Characteristics, management, and outcomes of patients with

- hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. *Lancet Gastroenterol Hepatol* [Internet]. 2017;2(2):103–11. Available from: [https://www.thelancet.com/journals/langas/article/PIIS2468-1253\(16\)30161-3/fulltext](https://www.thelancet.com/journals/langas/article/PIIS2468-1253(16)30161-3/fulltext)
12. McMahon B, Block J, Block T, Cohen C, Evans AA, Hosangadi A, et al. Hepatitis-Associated liver cancer: Gaps and opportunities to improve care. *J Natl Cancer Inst* [Internet]. 2016;108(4):1–6. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857154/>
  13. Kar P. Risk Factors for Hepatocellular Carcinoma in India. *J Clin Exp Hepatol* [Internet]. 2014;4(August):S34–42. Available from: <http://dx.doi.org/10.1016/j.jceh.2014.02.155>
  14. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. *Nat Rev Dis Prim* [Internet]. 2021;7(1). Available from: <http://dx.doi.org/10.1038/s41572-020-00240-3>
  15. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. alpha-fetoprotein, des-gamma carboxythrombin, and Lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. *Gastroenterology*. 2010;137(1):110–8.
  16. Song DS, Bae SH. Changes of HCC guidelines. 2012;258–67.
  17. Hassan-Kadle MA. The Diagnostic Challenges, Possible Etiologies and Lack of Researches of Hepatocellular Carcinoma in Somalia. *Open J*



- Gastroenterol [Internet]. 2017;07(03):115–23. Available from:  
<https://www.scirp.org/journal/PaperInformation.aspx?PaperID=75042>
18. Hassan-Kadle MA, Osman MS, Ogurtsov PP. Epidemiology of viral hepatitis in Somalia: Systematic review and meta-analysis study. World J Gastroenterol [Internet]. 2018;24(34):3927–57. Available from:  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141335/>
19. Omar AI. Frequency of cancer distribution in Somalia□: A four-year retrospective epidemiological study. 2021;06(01):6–12. Available from:  
<https://soror.somaliren.org.so/record/220#.Yu0VnBxBxzo>
20. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: Epidemiology, clinical characteristics, viral interactions and management. Ann Gastroenterol [Internet]. 2015;28(2):221–8. Available from:  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367211/>
21. Zhang J, Lin S, Jiang D, Li M, Chen Y, Li J, et al. Chronic hepatitis B and non-alcoholic fatty liver disease: Conspirators or competitors? Liver Int [Internet]. 2020;40(3):496–508. Available from:  
<https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.14369>
22. Cheng YL, Wang YJ, Kao WY, Chen PH, Huo TI, Huang YH, et al. Inverse Association between Hepatitis B Virus Infection and Fatty Liver Disease: A Large-Scale Study in Populations Seeking for Check-Up. PLoS One [Internet]. 2013;8(8). Available from:  
<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.00720>

23. Xiong J, Zhang H, Wang Y, Wang A, Bian J, Huang H, et al. Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: A meta-analysis. *Oncotarget* [Internet]. 2017;8(63):107295–302. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739814/>
24. Kim MN, Han K, Yoo J, Hwang SG, Ahn SH. Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver. *Aliment Pharmacol Ther* [Internet]. 2022;55(1):97–107. Available from: <https://pubmed.ncbi.nlm.nih.gov/34820871/>
25. Machado M V., Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: Meta-analysis of risk factors and comparison with hepatitis C infected patients. *J Gastroenterol Hepatol* [Internet]. 2011;26(9):1361–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/21649726/>
26. Chan AWH, Wong GLH, Chan HY, Tong JHM, Yu YH, Choi PCL, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. *J Gastroenterol Hepatol* [Internet]. 2017;32(3):667–76. Available from: <https://pubmed.ncbi.nlm.nih.gov/27547913/>
27. Singh MK, Das BK, Choudhary S, Gupta D, Patil UK. Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. *Biomed Pharmacother* [Internet]. 2018;106:991–1002. Available from:

<https://pubmed.ncbi.nlm.nih.gov/30119271/>

28. Rodríguez-Escaja C, Navascués C, González-Diéguez L, Cadahía V, Varela M, de Jorge MÁ, et al. Diabetes is not associated with an increased risk of hepatocellular carcinoma in patients with alcoholic or hepatitis C virus cirrhosis. *Rev Esp Enfermedades Dig*. 2021;113(7):505–11.
29. Azit NA, Sahran S, Meng LV, Subramaniam M, Mokhtar S, Nawi AM. Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country. *PLoS One* [Internet]. 2021;16(12 December):1–20. Available from: <http://dx.doi.org/10.1371/journal.pone.0260675>
30. Qi Y, Fan L, Ran D, Xu J, Wang Y, Wu J, et al. Main Risk Factors of Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. *J Oncol* [Internet]. 2021;2021. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528616/>
31. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: A population based case control study. *Gut* [Internet]. 2005;54(4):533–9. Available from: <https://gut.bmj.com/content/54/4/533>
32. Hassan-Kadle MA, Osman MM, Keles E, Eker HH, Baydili KN, Ahmed HM, et al. Clinical Characteristics of Patients with Hepatocellular Carcinoma: A Single-Center 3-Year Experience from Somalia. *Int J Hepatol* [Internet]. 2022;2022. Available from: <https://www.hindawi.com/journals/ijh/2022/3370992/>

33. Cho E, Cho HA, Jun CH, Kim HJ, Cho SB, Choi SK. A review of hepatocellular carcinoma in elderly patients focused on management and outcomes. In Vivo (Brooklyn) [Internet]. 2019;33(5):1411–20. Available from: <https://iv.iarjournals.org/content/33/5/1411>
34. Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: A literature review. J Cancer [Internet]. 2013;4(8):635–43. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805991/>
35. Subhani M, Sheth A, Ahmad B, Ryder S. How to interpret and manage abnormal liver blood test results in older people. Br J Hosp Med. 2021;82(8):34431345.
36. Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, et al. Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. J Formos Med Assoc [Internet]. 2020;119(10):1476–82. Available from: <https://pubmed.ncbi.nlm.nih.gov/32499209/>
37. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan. Gastroenterology [Internet]. 2008;135(1):111–21. Available from: <https://pubmed.ncbi.nlm.nih.gov/18505690/>
38. Kohsari M, Moradinazar M, Rahimi Z, Pasdar Y, Shakiba E. Liver Enzymes and Their Association with Some Cardiometabolic Diseases: Evidence from a Large Kurdish Cohort. Biomed Res Int. 2021;2021.

39. Alswat KA, Sanai FM, Altuwaijri M, Albenmousa A, Almadi M, Al-Hamoudi WK, et al. Clinical characteristics of patients with hepatocellular carcinoma in a middle eastern population. *Hepat Mon* [Internet]. 2013;13(5):1–8. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732662/>
40. Asaoka Y, Tateishi R, Nakagomi R, Kondo M, Fujiwara N, Minami T, et al. Frequency of and predictive factors for vascular invasion after radiofrequency ablation for hepatocellular carcinoma. *PLoS One*. 2014;9(11):1–8.
41. Whitehead TP, Robinson D, Allaway SL. The effects of cigarette smoking and alcohol consumption on serum liver enzyme activities: A dose-related study in men. *Ann Clin Biochem* [Internet]. 1996;33(6):530–5. Available from: <https://pubmed.ncbi.nlm.nih.gov/8937584/>
42. Petrick JL, Campbell PT, Koshiol J, Thistle JE, Andreotti G, Beane-Freeman LE, et al. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project. *Br J Cancer* [Internet]. 2018;118(7):1005–12. Available from: <http://dx.doi.org/10.1038/s41416-018-0007-z>
43. Mehlig K, Schult A, Björkelund C, Thelle D, Lissner L. Associations between alcohol and liver enzymes are modified by coffee, cigarettes, and overweight in a Swedish female population. *Scand J Gastroenterol* [Internet]. 2022;57(3):319–24. Available from: <https://doi.org/10.1080/00365521.2021.2009557>

44. Abdul-Wahab R. Hamad Khaled NA-K, Al-Daline SM, Al-Ani F.  
Effect of cigarette smoking on serum and salivary enzymes. Eur J  
Biomed Pharm Sci [Internet]. 2015;(January):107–20. Available from:  
[https://www.researchgate.net/publication/272892265\\_EFFECT\\_OF\\_CIGARETTE\\_SMOKING\\_ON\\_SERUM\\_AND\\_SALIVARY\\_ENZYME\\_FUNCTION](https://www.researchgate.net/publication/272892265_EFFECT_OF_CIGARETTE_SMOKING_ON_SERUM_AND_SALIVARY_ENZYME_FUNCTION)
  
45. Wannamethee SG, Shaper AG. Cigarette smoking and serum liver  
enzymes: The role of alcohol and inflammation. Ann Clin Biochem  
[Internet]. 2010;47(4):321–6. Available from:  
<https://pubmed.ncbi.nlm.nih.gov/20511375/>
  
46. Sahoo D, Rukmini M, Ray R. Quantitative Analysis of Serum Level  
Alanine and Aspartate Aminotransferases,  $\gamma$ -Glutamyl Transferase and  
Alkaline Phosphatase as Predictor of Liver Diseases. Am Int J Res  
Formal, Appl Nat Sci [Internet]. 2015;51–5. Available from:  
[citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.1065.4504&rep=rep1&type=pdf](http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.1065.4504&rep=rep1&type=pdf)
  
47. McGill MR. The past and present of serum aminotransferases and the  
future of liver injury biomarkers. EXCLI J [Internet]. 2016;15:817–28.  
Available from:  
<http://www.ncbi.nlm.nih.gov/pubmed/28337112>  
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5318690>
  
48. Schomaker S, Potter D, Warner R, Larkindale J, King N, Porter AC, et  
al. Serum glutamate dehydrogenase activity enables early detection of  
liver injury in subjects with underlying muscle impairments. PLoS One

[Internet]. 2020;15(5):1–13. Available from:

<http://dx.doi.org/10.1371/journal.pone.0229753>

49. Tae HL, Kim WR, Benson JT, Therneau TM, Melton LJ. Serum aminotransferase activity and mortality risk in a United States community. *Hepatology* [Internet]. 2008;47(3):880–7. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/hep.22090>
50. M.G. N, L.B. C, R.M. N. Biomarkers in nonalcoholic fatty liver disease. *Can J Gastroenterol Hepatol* [Internet]. 2014;28(11):607–18. Available from: <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L600975981>
51. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. *Hepatology* [Internet]. 2008;47(4):1363–70. Available from: <https://pubmed.ncbi.nlm.nih.gov/18366115/>
52. Giannini EG, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, et al. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. *Cancer* [Internet]. 2014;120(14):2150–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/24723129/>
53. Clark P. Serum markers for hepatocellular carcinoma. *Clin Liver Dis* [Internet]. 2016;8(2):29–33. Available from: <https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/cld.565>

54. Arango-Barrientos M, Navarro-Sierra S, Ocampo-Aristizábal LA, Muñoz-Maya OG, Zuleta-Tobón JJ, Hoyos-Duque SI, et al. Alpha-fetoprotein and gamma-glutamyltransferase in patients with liver cirrhosis and hepatocellular carcinoma. *Rev Colomb Gastroenterol* [Internet]. 2010;25(1):37–41. Available from: <https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/cld.565>
  
55. Jasirwan COM, Fahira A, Siregar L, Loho I. The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia. *BMC Gastroenterol* [Internet]. 2020;20(1):1–8. Available from: <https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-020-01365-1>
  
56. Manuc D, Preda CM, Sandra I, Baicus C, Cerban R, Constantinescu I, et al. Signification of Serum Alpha-Fetoprotein Levels in Cases of Compensated Cirrhosis and Hepatitis C Virus without Hepatocellular Carcinoma. *J Med Life* [Internet]. 2020;13(1):68–74. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175429/>
  
57. Zhang LX, Lv Y, Xu AM, Wang HZ. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma. *BMC Cancer* [Internet]. 2019;19(1):1–9. Available from: <https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-6011-8>
  
58. Ince V, Carr BI, Bag HG, Koc C, Usta S, Ersan V, et al. Gamma glutamyl transpeptidase as a prognostic biomarker in hepatocellular



cancer patients especially with >5 cm tumors, treated by liver transplantation. *Int J Biol Markers* [Internet]. 2020;35(2):91–5. Available from: <https://pubmed.ncbi.nlm.nih.gov/32436751/>

59. Zhang H, Gao C, Fang L, Yao SK. Increased international normalized ratio level in hepatocellular carcinoma patients with diabetes mellitus. *World J Gastroenterol* [Internet]. 2013;19(15):2395–403. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631993/>